About FabUTech™

Who we are

Founded by Chris Wiley, a biopharma Chemistry, Manufacturing, and Controls (CMC) leader with more than a decade of experience in biologics formulation, process development, and radiopharmaceutical manufacturing, FabUTech brings both scientific depth and practical development expertise. Chris contributed to three FDA-approved biologics at Pfizer, and most recently led the BLA submission for Zircaix, the first full length antibody Zr-89 radioconjugate to undergo FDA priority review, at Telix Pharmaceuticals. Chris now leads FabUTech with the goal of delivering impactful innovations at the intersection of biologics and radiopharmaceuticals that reach patients worldwide.

Alongside his role at FabUTech, Chris also leads HalfLife CMC, a consultancy dedicated to helping radiopharma innovators apply biologics-grade CMC strategies to their programs. Together, FabUTech and HalfLife CMC reflect his commitment to advancing innovations at the intersection of biologics and radiopharmaceuticals to reach patients worldwide.

Our Commitment

We are guided by a simple truth: better tools for manufacturing nuclear drug products mean more patients get the care they need. By partnering with developers, manufacturers, and suppliers, we aim to make nuclear biologics safer, more reliable, and more widely available.

Join Us

FabUTech is building partnerships with innovators, investors, and manufacturing leaders who share our vision. Together, we can shape the next generation of nuclear medicines.